TFP
ALNY icon

Tilia Fiduciary Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tilia Fiduciary Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21
Closed -$3.99K – 107
2023
Q2 		$3.99K Hold
21
– – ﹤0.01% 454
2023
Q1 		$4.21K Hold
21
– – ﹤0.01% 439
2022
Q4 		$4.99K Hold
21
– – ﹤0.01% 410
2022
Q3 		$4K Hold
21
– – ﹤0.01% 432
2022
Q2 		$3K Hold
21
– – ﹤0.01% 465
2022
Q1 		$3K Hold
21
– – ﹤0.01% 490
2021
Q4 		$4K Buy
+21
New +$3.9K ﹤0.01% 492

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tilia Fiduciary Partners's ALNY Position: Q3 2023 in Review

Tilia Fiduciary Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 21 shares — an estimated $3.99K sold.

Tilia Fiduciary Partners first reported a position in ALNY in Q4 2021 and held it in 7 quarters. The position peaked at $4.99K in Q4 2022. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Tilia Fiduciary Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 21 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $3.99K.
  • Tilia Fiduciary Partners first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Tilia Fiduciary Partners's Alnylam Pharmaceuticals position peaked at $4.99K in Q4 2022.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2023, filed 10 Oct 2023.